Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.49 |
| ▸ | MAOA | P21397 | 12/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14322492 | 0.84 | DRD2 (0.55) | PDPK1 | |
| SCHEMBL21821532 | 0.75 | CA1 (0.46) | — | |
| SCHEMBL14304242 | 0.73 | PDPK1 (0.55) | PDPK1 | |
| SCHEMBL12162260 | 0.72 | FFAR1 (0.37) | MAOBMAOA | |
| SCHEMBL16977037 | 0.72 | PTGDR2 (0.55) | — | |
| SCHEMBL15970743 | 0.71 | PDPK1 (0.53) | MAOBPDPK1 | |
| SCHEMBL14302869 | 0.71 | PDPK1 (0.53) | MAOBPDPK1 | |
| SCHEMBL12434066 | 0.71 | PDPK1 (0.53) | MAOBPDPK1 | |
| SCHEMBL27600869 | 0.71 | HTR2C (0.38) | — | |
| SCHEMBL15160059 | 0.71 | MAOB (0.38) | MAOBMAOAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205302-B2 | Anticoagulants; antilipemic agents; cardiovascular disorders | NIPPON SHINYAKU CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| CN-1301973-C | Heterocyclic derivatives and medicines | NIPPON SHINYAKU CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| EP-1400518-B1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | EP | disclosed |
| CN-1516690-A | Heterocyclic derivatives and medicines | �ձ���ҩ��ʽ���� | 2004-07-28 | — | — | CN | disclosed |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | NIPPON SHINYAKU CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1400518-A1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | CNR2, CNR1, GPR55 | MAOB 1961/4885MAOA 2069/4885PDPK1 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.